China Meheco(SH:600056) Zheng Quan Shi Bao Wang·2025-08-29 02:08Core Viewpoint - China National Pharmaceutical Group Corporation (China Pharmaceutical) is committed to sustainable development and integrating ESG principles into its corporate strategy and daily operations, while facing external competition and internal reform challenges [1][8]. Group 1: Financial Performance - In the first half of 2025, China Pharmaceutical achieved operating revenue of 17.076 billion yuan and a net profit attributable to shareholders of 294 million yuan [1]. Group 2: Green Manufacturing System Upgrade - China Pharmaceutical is actively promoting low-carbon transformation across its supply chain, with subsidiaries Tianfang Pharmaceutical and Sanyo Pharmaceutical recognized as national-level green factories, with Sanyo achieving "zero-carbon factory" status [2]. - Tianfang Pharmaceutical has invested in a 3.7MW distributed photovoltaic system and implemented intelligent upgrades to its fermentation tank motor systems, enhancing energy efficiency and reducing emissions [2]. Group 3: Innovation and R&D - The company emphasizes innovation as a core driver of development, with a research team of 317 members and a 3.06% increase in R&D expenses in the first half of 2025 [3]. - The company has made significant progress in product development, obtaining production approvals for five products and filing 17 invention patents [3]. Group 4: Social Responsibility - China Pharmaceutical is dedicated to expanding healthcare accessibility, particularly in remote areas, through partnerships with local governments and healthcare institutions [4]. - The company has collaborated with UNICEF to provide maternal and infant medical equipment in Uzbekistan, enhancing local healthcare capabilities [4]. Group 5: Governance Structure Optimization - The company has established a three-tier ESG governance structure to ensure comprehensive oversight and management of ESG initiatives [7]. - In the first half of 2025, China Pharmaceutical achieved ISO37301 compliance management system certification and revised several governance documents to enhance decision-making transparency and protect shareholder rights [7]. Group 6: ESG Commitment - China Pharmaceutical has received an A rating in the 2025 ESG assessment, positioning itself as an industry benchmark in green development, social responsibility, and governance innovation [8].